We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

NT-proBNP Underestimates Heart Failure Risk for Certain Patients

By LabMedica International staff writers
Posted on 03 May 2022
Print article
Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)
Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)

The N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics, according to a cohort study suggesting the importance of sex and race in interpreting risk for people free of HF at baseline.

N-terminal pro B-type natriuretic peptide (NT-proBNP) is an inactive peptide released along with the active peptide hormone BNP when the walls of the heart are stretched or there is pressure overload on the heart e.g. by fluid overload. BNP then acts on the kidneys causing fluid and sodium loss in the urine and mild vasodilation so releasing the pressure.

Cardiologists at the Brigham and Women’s Hospital (Boston, MA, USA) and their colleagues wanted to determine whether physiologic determinants of NT-proBNP concentrations account for sex and race differences, and to more uniformly predict HF risk using NT-proBNP in these demographic subgroups. The team enrolled 5,191 individuals from visit five averaged 76.0 ± 5.2 years of age. Men and Black people each accounted for 41% and 20%, respectively, of the overall cohort. The contribution of clinical, anthropometric, echocardiographic, and laboratory parameters to sex- and race-based differences in NT-proBNP concentration was assessed at visit five using linear regression. Participants included were free of HF in midlife.

The investigators reported that the median (IQR) NT-proBNP concentration was 124 (64-239) pg/mL. In both midlife and late life, NT-proBNP concentration was lowest in Black men (median [IQR] concentration: visit 2, 30 [14-67] pg/mL; visit five, 74 [34-153] pg/mL) and highest in White women (median [IQR] concentration: visit 2, 70 [42-111] pg/mL; visit, five, 154 [82-268] pg/mL). Substantial differences in the absolute risk of incident HF or death existed across the sex- and race-based categories at any NT-proBNP concentration (e.g., 7-fold [rate ratio, 6.7] and 3-fold [rate ratio, 2.7] difference at visit two and visit five, respectively, at guideline-recommended thresholds) with higher risk consistently observed among Black men and lower risk in White women.

The authors concluded that in their study, sex- and race-based differences in NT-proBNP persisted after accounting for known physiologic determinants. Absolute risk associated with a given value of NT-proBNP varied substantially by sex and race. Consideration of NT-proBNP values in the context of sex and race allows for more uniform prediction of absolute risk across important demographic subgroups. The study was published on April 27, 2022 in the journal JAMA Cardiology.

Related Links:
Brigham and Women’s Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more